Richard S Smith

This inventor holds 16 USPTO granted patents, primarily in Diagnostic Systems. Top assignees: Scripps Research Institute, Scripps Clinic and Research Foundation. Active years: 1989-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard S Smith. Retrieved from https://idiyas.com/inventor/richard-s-smith-co1obw8z

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16

% Patents Active = 100.0

Average Co-Inventor Count = 3.5

ph-index = 10

Forward Citations = 221(Granted Patents)

Company Filing History:

12 out of 1,208

Scripps Research Institute

patents

4 out of 122

Scripps Clinic and Research Foundation

patents

Years Active: 1989-1998

Loading Chart...

Areas of Expertise:

Polypeptides

Antibodies

Diagnostic Methods

Apolipoprotein E

Epstein-Barr Virus

Human Papillomavirus

Glycosylated Hemoglobin

APO AI

Recombinant Antigens

Quantification Systems

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5814467 - APO AI polypeptides, diagnostic methods and systems for quantifying APO (1998-09-29),

2. 5786206 - DNA encoding recombinant lipoprotein antigens (1998-07-28),

3. 5717065 - Synthetic polypeptides and antibodies related to epstein-barr virus (1998-02-10),

4. 5486453 - Antibodies to human papillomavirus latent proteins, diagnostic systems (1996-01-23),

5. 5473039 - Polypeptide analogs of apolipoprotein E, diagnostic systems and methods (1995-12-05),

6. 5408038 - Nonnatural apolipoprotein B-100 peptides and apolipoprotein (1995-04-18),

7. 5401627 - Antibodies to human papillomavirus latent proteins, diagnostic systems (1995-03-28),

8. 5182364 - Polypeptide analogs of apolipoprotein E (1993-01-26),

9. 5180806 - Polypeptides and compositions of human papillomavirus latent proteins, (1993-01-19),

10. 5177189 - Polypeptide analogs of Apolipoprotein E (1993-01-05),

11. 5169937 - Method for producing stable glycosylated hemoglobin (1992-12-08),

12. 5168045 - Diagnostic systems and methods using polypeptide analogs of (1992-12-01),

13. 5116725 - Assay for Epstein-Barr virus infection with solid phase bound synthetic (1992-05-26),

14. 5055396 - Diagnostic methods and systems for quantifying APO AI (1991-10-08),

15. 4876188 - Novel immunochemical method for assaying stable glycosylated hemoglobin (1989-10-24),

Title: The Innovative Contributions of Richard S. Smith

Introduction

Richard S. Smith is a prominent inventor based in Del Mar, California, known for his significant contributions to the field of biotechnology. With a total of 16 patents to his name, Smith has made remarkable advancements in diagnostic methods and therapeutic applications related to lipoproteins.

Latest Patents

Among his latest patents are the APO AI polypeptides and diagnostic methods and systems for quantifying APO. This invention describes an Apo AI polypeptide capable of immunologically mimicking an Apo AI epitope. The polypeptide is useful in diagnostic methods and systems for detecting Apo AI in vascular fluid samples and for the preparation of anti-Apo AI antibodies. Additionally, the polypeptide is beneficial in therapeutic methods for increasing esterified cholesterol in human patients. Another notable patent involves DNA encoding recombinant lipoprotein antigens. This patent outlines methods and compositions for determining the level of low-density lipoproteins (LDL) in plasma. The native apoprotein B-100 (apo B-100) present in LDL particles is immunologically mimicked by a polypeptide of the invention. A preferred polypeptide is a fusion protein that simultaneously mimics native apo B-100 and native apo A-I. Improved assay systems and methods for determining HDL and LDL levels in body fluid samples are also described.

Career Highlights

Richard S. Smith has had a distinguished career, working with esteemed organizations such as The Scripps Research Institute and the Scripps Clinic and Research Foundation. His work has significantly impacted the understanding and treatment of lipid-related disorders.

Collaborations

Throughout his career, Smith has collaborated with notable colleagues, including Linda K. Curtiss and Joseph L. Witztum. These collaborations have further enhanced the quality and reach of his innovative work.

Conclusion

Richard S. Smith's contributions to biotechnology through his patents and collaborations have made a lasting impact on the field. His innovative approaches to diagnostics and therapeutics continue to influence research and development in lipoprotein-related health issues.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]